TRDA

Aug 5, 2026, 00:00 UTC

Entrada Therapeutics reported Q2 2026 financial results with revenue of $0.9 million, a net loss of $42.8 million, and diluted EPS of -$1.01, compared to revenue of $2.0 million and a net loss of $43.1 million in Q2 2025.